Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (106)

« Back to Publications

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

Gibson V. et al, (2026), Nat Commun, 17

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

Schmid P. et al, (2026), Nat Cancer

Real-world obesity prevalence and history in 79 271 patients receiving systemic anticancer therapy across 13 cancer types in England (2013-2023).

Perletta V. et al, (2026), ESMO Real World Data Digit Oncol, 12

Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Schmid P. et al, (2026), Clin Cancer Res

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.

Beernaert B. et al, (2026), Sci Adv, 12

Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study

Schmid P. et al, (2026), Annals of Oncology

Clinical Impact of Next-Generation Sequencing-Guided Targeted Therapies in Advanced Cancer: A Systematic Review and Meta-Analysis.

Kazmi F. et al, (2025), Clin Oncol (R Coll Radiol), 48

A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.

Cortés J. et al, (2025), Clin Cancer Res, 31, 4953 - 4963

Figure 3 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2025)

Figure 4 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2025)

Figure 6 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2025)

Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2025)

Figure 5 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2025)

Figure 1 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2025)

Figure 2 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface

Cheng VWT. et al, (2025)

Load More

1
2
3
4
5
6
7
...
»